Below are the most recent publications written about "Kidney Neoplasms" by people in Profiles.
-
Korn P, Essien M, Pallauf M, Cheaib J, Lokeshwar S, Herrera-Caceres JO, Small A, Raskolnikov D, Kleinmann N, Shvero A, Matin SF, Labbate C, Kaimakliotis H, Tachibana I, Linehan J, Choe J, Shah O, Movassaghi M, Huang W, Persily J, Perecman A, Canes D, Pessoa RR, Potretzke A, Raman JD, Singla N. Renal function outcomes following endoscopic management of upper tract urothelial carcinoma. World J Urol. 2026 May 22; 44(1).
-
Ky B, Liu T, Margulies KB, Mitchell JD, Haas NB, Gareen IF, Thangarajah M, Sicks JD, Domenico C, Narayan VK, Smith AM, Wilcox NS, Mittal K, Rhee JW, Armenian SH, Saphner T, Paul AK, Gartrell BA, Zaha VG, Anari F, Wong RL, Townsend RR, Wagner LI. Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension. 2026 Jul; 83(7):e26016.
-
Korn P, Pallauf M, Herrera-Caceres JO, Lokeshwar S, Essien M, Small A, Raskolnikov D, Kleinmann N, Shvero A, Matin SF, Labbate C, Kaimakliotis H, Tachibana I, Linehan J, Choe J, Shah O, Movassaghi M, Huang W, Persily J, Perecman A, Canes D, Pessoa RR, Potretzke A, Raman JD, Singla N. Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma. World J Urol. 2026 May 19; 44(1).
-
Aslan B, Rigiroli F, Brook A, Brook OR. Clear Cell Renal Cell Carcinoma Metastases Visibility: Split-Bolus Single Scan Versus Portal Venous Phase CT. J Comput Assist Tomogr. 2026 May-Jun 01; 50(3):383-389.
-
Abu-Remaileh M, Stransky LA, Bhalerao N, Shirole NH, Jiang Q, Saad E, Machaalani M, Vigeant SM, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri TK, Pitarresi JR, Carr SA, Udeshi ND, Kaelin WG. Targeting of HIF2-driven cachexia in kidney cancer. Nat Med. 2026 Jan; 32(1):245-257.
-
Khan S, Rogers S, Haghani L, Huynh D, MillnerBalagtas D, Wilson S, Figueira T, Yates J, Resnick NJ, Li NP. Image-Guided Thermal Ablation of Upper Pole Renal Lesions =4 cm: Safety and Effectiveness. J Vasc Interv Radiol. 2026 01; 37(1):107895.
-
Herrera-Caceres JO, Wettstein M, Matin SF, Labbate C, Potretzke A, Rodriguez R, Singla N, Pallauf M, Huang W, Nagpal S, Kleinmann N, Shvero A, Small A, Green B, Linehan J, Choe J, Shah O, Rai A, Kaimakliotis H, Tachibana I, Canes D, Perecman A, Raman JD. Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis. Urol Oncol. 2025 Dec; 43(12):697.e1-697.e9.
-
Lee D, Jeon KH, Jung J, Han K, Cho MH, Cho IY, Shin DW. Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study. Rheumatology (Oxford). 2025 06 01; 64(6):3458-3467.
-
Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus GT, B?rcs?k J, Sztupinszki Z, Hanlon T, Diossy M, Vizkeleti L, Stormoen DR, Csabai I, Pappot H, Vijai J, Offit K, Ried T, Sethi N, Mouw KW, Spisak S, Pathania S, Szallasi Z. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. Sci Rep. 2023 11 23; 13(1):20567.
-
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, B?ttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, B?chler T, Massari F, Seront E, Calabr? F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, K?ronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? Eur Urol Oncol. 2024 02; 7(1):102-111.